<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344407</url>
  </required_header>
  <id_info>
    <org_study_id>999915071</org_study_id>
    <secondary_id>15-I-N071</secondary_id>
    <nct_id>NCT02344407</nct_id>
  </id_info>
  <brief_title>Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)</brief_title>
  <official_title>Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Ebola virus disease (EVD) affects many people in Liberia and other countries in West
      Africa. It is caused by the Ebola virus and makes people sick with fever, headache, vomiting,
      diarrhea, rash, and bleeding. About half the people with EVD die. There is no approved
      treatment for it. Researchers are studying two Ebola vaccines. The vaccines do not cause
      Ebola.

      Objectives:

      - To study the safety and efficacy of two Ebola vaccines.

      Eligibility:

      - Adults 18 and older who live in Liberia and are at risk for Ebola infection but have never
      had Ebola.

      Design:

        -  Participants will give information including birthdate, gender, occupation, and location
           of home. They will give contact information for themselves and 2 alternate contacts.
           They will give a history of their contact with people with Ebola. Some participants may
           have a physical. They may have blood taken.

        -  Participants will be injected with either an Ebola vaccine or a placebo with a needle in
           the upper arm. The placebo is a salt solution.

        -  Participants will have blood taken.

        -  Participants will be watched for 30 minutes.

        -  Participants will return to the clinic 1 week and 1 month after they get the shot. They
           will have blood taken.

        -  After that, participants will be contacted monthly to discuss how they are feeling. They
           may be contacted by phone, may visit the clinic, or may have a home visit.

        -  The study ends 8-12 months after participants get the shot. If one of the vaccines works
           against Ebola and does not have many side effects, participants can get the vaccine if
           they did not get it in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ebola virus disease (EVD) in West Africa is spreading rapidly, and there is a critical need
      for a vaccine to prevent EVD. There are two candidate Ebola virus vaccines, the chimpanzee
      adenovirus 3 (ChAd3-EBO Z)-based vaccine and the Vesicular Stomatitis virus
      (VSVdeltaG-ZEBOV)-based vaccine. This study will evaluate both of these vaccines in a
      randomized, double-blind, controlled, 3-arm study in Liberia. Each vaccine will be compared
      against the same active control. Because there are limited data on the safety of these
      vaccines, the initial phase (phase 2) of the study will include the collection of more
      detailed data on safety and will define the immune response elicited by each vaccine in the
      first 600 volunteers. With the decline in new cases of Ebola virus infection the phase 3
      component was no longer deemed to be feasible and, following safety, ethical and FDA
      approve/concurrence, the study was amended to a more robust, 1,500 person phase 2 design.

      With the amendment to only a phasae 3 study the endpoint reverted to the phase 2 endpoint of
      safety and immunogenicity.

      Participants aged 18 year and older will be enrolled at health clinics in Monrovia, Liberia
      over 4 months. A single dose of the assigned agent will be administered. Participants in
      phase 2 will undergo blood draw and assessment of adverse events (AEs) and signs and symptoms
      of Ebola infection at 1 week and 1 month after vaccination, and monthly assessment of AEs and
      signs and symptoms of Ebola thereafter. Participants in phase 3 will undergo monthly
      assessment of AEs and signs and symptoms of Ebola infection after vaccination. All
      participants will be followed for 8 to 12 months.

      This clinical trial to evaluate vaccine efficacy will provide an accurate assessment of the
      benefits and risks associated with each candidate vaccine and inform policy on wider scale
      vaccination in other countries.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 20, 2015</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events.</measure>
    <time_frame>One month</time_frame>
    <description>Number of Participants Experiencing Serious Adverse Events in First 30 Days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity Measures (ELISA and Neutralization Antigen-specific Assays for Antibody.</measure>
    <time_frame>One month</time_frame>
    <description>Antibody Response at 1-Month (EU/mL) for Participants Without Elevated Levels at Entry</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1500</enrollment>
  <condition>Ebola Virus</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ChAd3-EBO Z</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VSVG-ZEBOV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VSVG-ZEBOV</intervention_name>
    <description>The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAd3-EBO Z</intervention_name>
    <description>The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        The inclusion criteria for the study are broad reflecting the target population that would
        eventually receive an efficacious vaccine.

          -  Informed consent

          -  Age greater than or equal to 18 years

          -  Likely to be in the surrounding area of the vaccination center for at least one year.

        EXCLUSION CRITERIA:

          -  Fever greater than or equal to 38.0 degrees Celsius

          -  History of EVD (self-report)

          -  Current pregnancy (a negative urine pregnancy test is required for women of
             child-bearing potential)

          -  Breast-feeding an infant

          -  Any condition which would limit the ability of the participant to meet the
             requirements of the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Clifford Lane, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liberian Ministry of Health and Social Welfare</name>
      <address>
        <city>Monrovia</city>
        <country>Liberia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Liberia</country>
  </location_countries>
  <reference>
    <citation>Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011 Mar 5;377(9768):849-62. doi: 10.1016/S0140-6736(10)60667-8. Review.</citation>
    <PMID>21084112</PMID>
  </reference>
  <reference>
    <citation>Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa--clinical manifestations and management. N Engl J Med. 2014 Nov 27;371(22):2054-7. doi: 10.1056/NEJMp1413084. Epub 2014 Nov 5.</citation>
    <PMID>25372854</PMID>
  </reference>
  <reference>
    <citation>Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012 Jan 4;4(115):115ra2. doi: 10.1126/scitranslmed.3002925.</citation>
    <PMID>22218691</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <results_first_submitted>May 25, 2017</results_first_submitted>
  <results_first_submitted_qc>May 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 1, 2017</results_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zaire Ebola Virus Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ChAd3-EBO Z</title>
          <description>ChAd3-EBO Z
ChAd3-EBO Z: The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.</description>
        </group>
        <group group_id="P2">
          <title>VSVG-ZEBOV</title>
          <description>VSVG-ZEBOV
VSVG-ZEBOV: The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Saline)</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="500"/>
                <participants group_id="P3" count="500"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="492"/>
                <participants group_id="P2" count="491"/>
                <participants group_id="P3" count="494"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ChAd3-EBO Z</title>
          <description>ChAd3-EBO Z
ChAd3-EBO Z: The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.</description>
        </group>
        <group group_id="B2">
          <title>VSVG-ZEBOV</title>
          <description>VSVG-ZEBOV
VSVG-ZEBOV: The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Saline)</title>
          <description>Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="500"/>
            <count group_id="B2" value="500"/>
            <count group_id="B3" value="500"/>
            <count group_id="B4" value="1500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="25" upper_limit="38"/>
                    <measurement group_id="B2" value="29" lower_limit="24" upper_limit="36"/>
                    <measurement group_id="B3" value="30" lower_limit="24" upper_limit="39"/>
                    <measurement group_id="B4" value="30" lower_limit="24" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="177"/>
                    <measurement group_id="B4" value="549"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="313"/>
                    <measurement group_id="B3" value="323"/>
                    <measurement group_id="B4" value="951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Liberia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="500"/>
                    <measurement group_id="B3" value="500"/>
                    <measurement group_id="B4" value="1500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Contact past month with someone who had Ebola</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Work involves contact with persons with Ebola</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV Positive</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Syphilis positive</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IgG antibody level (EU/mL)</title>
          <units>EU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" lower_limit="44" upper_limit="135"/>
                    <measurement group_id="B2" value="81" lower_limit="49" upper_limit="141"/>
                    <measurement group_id="B3" value="79" lower_limit="50" upper_limit="148"/>
                    <measurement group_id="B4" value="78" lower_limit="47" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive antibody response</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events.</title>
        <description>Number of Participants Experiencing Serious Adverse Events in First 30 Days</description>
        <time_frame>One month</time_frame>
        <population>All Participants Randomized</population>
        <group_list>
          <group group_id="O1">
            <title>ChAd3-EBO Z</title>
            <description>ChAd3-EBO Z
ChAd3-EBO Z: The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.</description>
          </group>
          <group group_id="O2">
            <title>VSVG-ZEBOV</title>
            <description>VSVG-ZEBOV
VSVG-ZEBOV: The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Saline)</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events.</title>
          <description>Number of Participants Experiencing Serious Adverse Events in First 30 Days</description>
          <population>All Participants Randomized</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Each active vaccine is compared to the placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Chi-squared</method>
            <method_desc>Bernards Exact Test Chi-square</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Chi-squared</method>
            <method_desc>Barnard Exact Test Chi-square</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity Measures (ELISA and Neutralization Antigen-specific Assays for Antibody.</title>
        <description>Antibody Response at 1-Month (EU/mL) for Participants Without Elevated Levels at Entry</description>
        <time_frame>One month</time_frame>
        <population>Participants with 1-month antibody data without elevated antibody levels at entry</population>
        <group_list>
          <group group_id="O1">
            <title>ChAd3-EBO Z</title>
            <description>ChAd3-EBO Z
ChAd3-EBO Z: The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.</description>
          </group>
          <group group_id="O2">
            <title>VSVG-ZEBOV</title>
            <description>VSVG-ZEBOV
VSVG-ZEBOV: The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Saline)</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Measures (ELISA and Neutralization Antigen-specific Assays for Antibody.</title>
          <description>Antibody Response at 1-Month (EU/mL) for Participants Without Elevated Levels at Entry</description>
          <population>Participants with 1-month antibody data without elevated antibody levels at entry</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="471"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="621" lower_limit="565" upper_limit="682"/>
                    <measurement group_id="O2" value="1000" lower_limit="910" upper_limit="1099"/>
                    <measurement group_id="O3" value="75" lower_limit="69" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Linear regression (analysis of covariance) adjusted for baseline antibody level</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance adjusting for baseline antibody level</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First 30 days after vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ChAd3-EBO Z</title>
          <description>ChAd3-EBO Z
ChAd3-EBO Z: The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.</description>
        </group>
        <group group_id="E2">
          <title>VSVG-ZEBOV</title>
          <description>VSVG-ZEBOV
VSVG-ZEBOV: The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Saline)</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pheumocystis jirovecii pheumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Greg Grandits</name_or_title>
      <organization>Division of Biostatistics, University of Minnesota</organization>
      <phone>612-626-9033</phone>
      <email>grand001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

